Abstract 158P
Background
Single-cell RNA sequencing (scRNA-seq) has the ability to unveil uncommon cell populations. However, due to the high demand for tissue quality and cell viability, currently most scRNA-seq for pancreatic cancer was performed by surgical specimen or biopsy from metastatic sites. This study aims to establish a practical experience to help scientists perform primary pancreatic tumor scRNA-seq using EUS-FNB samples in real-world practice.
Methods
Two punctures from the same lesion using the same needle, without applying suction (Non-suction group) and with a negative pressure of 5 ml (Suction group) were evaluated. Single cell RNA sequencing libraries were prepared with Chromium Single cell 5’ Reagent Kits v2 (10X Genomics, USA) following the manufacturer’s protocol.
Results
A total of 20 patients were enrolled. The median age was 65.1 years old (range 46.6-83.2). Suction group achieved a cell preparation success rate of 80% (16/20) which was significantly higher than the 10% (2/20) success rate in the non-suction group (p<0.001). After the establishment of cell preparation protocol, we generate single-cell RNA transcriptomes for four patients, including two early stage (9,632 cells) and two late stage (4,592 cells). After quality control, 11,950 single cells were feasible for downstream analysis. Overall, 66% of cells (7,842) belonged to early stage and 34% (4,108) belonged to late stage. 12 major cell subtypes were identified across early and late stage. The proportion of cancer cells cluster-4 was significantly higher in late stage. Differentially expressed genes analysis showed UBE2C is the most highly expressed gene in cancer cells cluster-4. As external validation, in TCGA PAAD dataset, we found UBE2C high expression pancreatic cancer had significantly poor survival.
Conclusions
EUS-FNB with a negative pressure of 5 ml is feasible for single-cell sequencing in daily practice. A UBE2C high-expression subclone exists in early-stage pancreatic cancer and correlates with poor prognosis, potentially becoming a new therapeutic target in future studies.
Clinical trial identification
Protocol number: NCT05767697 Release date: 02 March, 2023.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
National Health Research Institutes.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
551P - Real-world incidence and outcomes of immune-related adverse events in NSCLC patients
Presenter: Andrea Knox
Session: Poster Display
Resources:
Abstract
552P - TROPION-Lung05: Datopotamab deruxtecan (Dato-DXd) in Asian patients (pts) with previously treated non-small cell lung cancer (NSCLC) with actionable genomic alterations (AGAs)
Presenter: Yasushi Goto
Session: Poster Display
Resources:
Abstract
553P - Preceding plasma EGFR vs upfront tissue NGS for advanced NSCLC in the Chinese population: A single centre experience in Hong Kong
Presenter: Janet Du
Session: Poster Display
Resources:
Abstract
554P - Comparison of the analytical performance of endobronchial ultrasound-guided transbronchial needle aspiration and other sampling methods for the Oncomine Dx target test: An observational study
Presenter: Kazuhito Miyazaki
Session: Poster Display
Resources:
Abstract
555P - Quality of life in patients with stage IV non-small cell lung cancer and the influence of druggable mutations over time: A prospective, territory-wide study in Hong Kong
Presenter: Jason C S Ho
Session: Poster Display
Resources:
Abstract
556P - Results from the phase I study on efficacy and safety of iruplinalkib (WX-0593) for anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) patients who received prior second-generation ALK tyrosine kinase inhibitors (TKIs)
Presenter: xuezhi Hao
Session: Poster Display
Resources:
Abstract
557P - Longitudinal plasma proteomic profiling of EML4-ALK positive lung cancer receiving ALK-TKIs therapy
Presenter: Shasha Wang
Session: Poster Display
Resources:
Abstract
558P - Treatment duration and adherence of brigatinib as second-line treatment after crizotinib for ALK+ NSCLC in South Korea
Presenter: Jeong Eun Lee
Session: Poster Display
Resources:
Abstract
559P - Comprehensive survey of AACR GENIE database revealed a wide range of TMB distribution among all three classes (I, II, III) of BRAF mutated NSCLC
Presenter: Zhaohui Arter
Session: Poster Display
Resources:
Abstract
560P - Triple-targeted therapy of dabrafenib, trametinib and osimertinib for the treatment of acquired BRAF V600E mutation after progression on EGFR-TKIs in advanced EGFR-mutant NSCLC
Presenter: Chengdi Weng
Session: Poster Display
Resources:
Abstract